Severe neonatal unconjugated hyperbilirubinemia, with the risk of bilirubin encephalopathy or kernicterus in severe, untreated cases, occurs when bilirubin production exceeds the body's ability to eliminate it. The causes of neonatal hyperbilirubinemia are multifactorial and comprise increased hemolysis on the one hand, and diminished bilirubin conjugation on the other. In recent years, many of these etiologies have been found to have a genetic origin. Sometimes hereditary factors act independently, but in other circumstances, single mutations which ordinarily do not produce disease in and of themselves, may result in severe hyperbilirubinemia as a result of interaction with other mutated genes. Of cardinal importance to this discussion is the concept of the human genome, whereby the thousands of genes of which it is comprised may interact one with the other, or with the environment, exacerbating the severity of jaundice in certain individuals, and protecting against hyperbilirubinemia in others. Genetic interactions have been demonstrated combining increased bilirubin production with diminished bilirubin conjugation, resulting in severe hyperbilirubinemia. Appreciation of the multiplicity of genetic interactions is of importance in our evaluation of the neonate with severe hyperbilirubinemia, in our attempts to prevent future cases of kernicterus, and in genetic counseling of families who have had an infant with severe neonatal hyperbilirubinemia. Gene therapy for the most severe of these inherited defects of bilirubin conjugation, Crigler-Najjar syndrome type 1, might become a reality in future years.
A. INTRODUCTION Neonatal Jaundice and Kernicterus
Neonatal jaundice is a commonly encountered entity, with some degree of yellowness of the skin or sclera, indicating a serum total bilirubin (STB) concentration of at least 5-6 mg/dL, occurring in about 60% of otherwise healthy, term neonates during the first days of life [Maisels 1999 ]. In most cases, the STB concentrations do not exceed the normal range, the upper limit for which may be defined as the 95 th percentile for hour of life [Bhutani et al. 1999] . Depending on the patient group under consideration, STB values peak on the 3 rd to 4 th day of life, the 95 th percentile at this age corresponding to STB concentrations of 15.0 mg/dL to 17.0 mg/dL [Maisels 2000 ]. Not every jaundiced newborn necessarily becomes endangered by hyperbilirubinemia, as in only a fraction of cases do the STB concentrations reach very high levels.
Rarely, dangerously high STB levels may be reached. Should the plasma bilirubin concentration exceed the capacity of plasma albumin to bind it, free bilirubin will accumulate. Free bilirubin has the capacity to cross the blood-brain barrier and become deposited in the basal ganglia and other areas of the brain, and as a result, bilirubin encephalopathy, or permanent, irreversible brain damage called kernicterus, may ensue. This devastating condition is the reason that neonatal hyperbilirubinemia is at the forefront of the concerns of those involved in neonatal care.
*Address correspondence to this author at the Department of Neonatology, Shaare Zedek Medical Center, PO Box 3235, Jerusalem 91031, Israel; Tel: 972-2-655-5643; Fax: 972-2-652-0689; E-mail: kaplan@cc.huji.ac.il In Westernized countries, for several decades prior to the 1990s, kernicterus was seldom encountered, as STB concentrations were for the most part prevented from exceeding 20.0 mg/dL. This concept was derived from the outcome of Rh isoimmunized neonates, who rarely developed kernicterus provided STB values were kept below this concentration. However, in recent years, over 125 cases of kernicterus have been recorded in an informal USA based Kernicterus Registry, some of which have been recently published [Johnson et al. 2002] . Cases of kernicterus have been reported from other countries as well, including Canada [Moore and Perlman 1999] , The Netherlands [Govaert et al. 2003 , Straver et al. 2002 , Oman [Nair and Al Khusaiby 2003] , Denmark [Ebbesen 2000] , and New Zealand [Stanley 1997] . A more liberal attitude towards neonatal hyperbilirubinemia [Watchko and Oski 1983 , Newman and Klebanoff 1993 , Newman and Maisels 1990 , the belief, subsequently disproved [Maisels 1995] , that kernicterus will not occur in the absence of hemolysis or in cases in whom breast-feeding is the only risk factor for jaundice, and a growing trend to mandatory early discharge, prior to STB concentrations peaking [Braveman et al. 1995] , have all contributed to this tragedy . Evidence that bilirubin itself may bestow beneficial antioxidant properties, may also have played its part in consolidating this approach [Stocker et al. 1987 ].
Imbalance Between Production and Conjugation of Bilirubin
In the majority of cases of neonatal jaundice the serum bilirubin is of the unconjugated, or indirect reacting type. Conjugated, or direct reacting bilirubin does not cross the blood brain barrier and does not cause bilirubin encephalopathy. Therefore, for the purpose of this review, only unconjugated bilirubinemia will be discussed.
The concentration of bilirubin in the serum at any point in time is dependent on the amount of bilirubin being produced, minus the quantity of bilirubin being eliminated, primarily by conjugation, from the body. As long as there is equilibrium between these processes, STB concentrations will remain within normal limits, and should rarely exceed the 95 th percentile for hour of life. However, should bilirubin production exceed bilirubin elimination, its concentration may increase in the serum and, in extreme situations, reach dangerous levels .
The concept of imbalance between production and conjugation of bilirubin in the pathogenesis of neonatal jaundice has been demonstrated mathematically using a "production-conjugation index" . This index is comprised of values for blood carboxyhemoglobin corrected for ambient CO (an index of heme catabolism and therefore of bilirubin production ), divided by serum total conjugated bilirubin concentration (reflecting bilirubin conjugation ). The index therefore represents the combined forces of these processes. For the most part, in a cohort of healthy, term neonates values for the index increased in concert with STB values, thus confirming the "imbalance" concept . In this review the emphasis will be placed on the concept of equilibrium, or lack thereof, between the respective roles of production and conjugation of indirect bilirubin in the protection against, or pathogenesis of, jaundice.
The Genome and Neonatal Hyperbilirubinemia
The genetic code for many of the metabolic steps involved in the formation of bilirubin and its subsequent conjugation has been elucidated in recent years, and many deficiencies in bilirubin metabolism can today be explained by genetic mutations. Of cardinal importance to this discussion is the concept of the human genome, whereby the thousands of genes of which it is comprised may interact one with the other, and with the environment, exacerbating the severity of jaundice in certain individuals, and protecting against hyperbilirubinemia in others. Individually, some of these genetic mutations may be insufficient to result in severe jaundice. However, in certain instances, genetic interactions have been demonstrated combining increased bilirubin production with diminished bilirubin conjugation, resulting in severe hyperbilirubinemia. [Kaplan 1997 ]. Discovery of some of these mutations may have clinical implications, as therapeutic modalities may be directed either directly against the mutated gene, or against the phenotypic result of the mutation. Some hereditary conditions which may lead to neonatal hyperbilirubinemia are listed in Table 1 .
B. PHYSIOLOGY OF BILIRUBIN FORMATION AND ELIMINATION
Excellent reviews of the metabolism of bilirubin exist [Inyangi et al. 1998 , Maisels 1999 . Therefore, in order to allow the reader full appreciation of the concept of imbalance between production and conjugation of bilirubin in the pathogenesis of neonatal hyperbilirubinemia, these processes will be only briefly summarized below. The schema of the production and A. Increased heme catabolism
1.
Ethnicity, familial Asian, Japanese Navajo Indian Specific Greek Islanders Jaundice in a previous sibling conjugation of bilirubin processes is illustrated diagrammatically in Figure 1 .
Bilirubin Production
Bilirubin is the oxidative product of the protoporphyrin portion of the heme group of proteins. More than 80% of the bilirubin produced in the human body derives from heme catabolism liberated from senescent red cells (RBC). The remainder of heme derives from other hemoproteins such as myoglobin and cytochrome P-450. Heme is degraded to biliverdin, and the latter subsequently metabolized to bilirubin. These processes are catalyzed by the enzymes heme oxygenase and biliverdin reductase, respectively. For each molecule of bilirubin derived by this process, equimolar quantities of carbon monoxide are produced. The latter binds to hemoglobin to form carboxyhemoglobin (COHb) in which form it is transported to the lungs and exhaled. Unconjugated, or indirect reacting bilirubin, enters the serum and is transported to the liver bound to albumin. Under physiological conditions, sufficient serum albumin should be available to bind the amounts of bilirubin produced and free (unbound) bilirubin is unlikely to accumulate in the serum. The binding of bilirubin to albumin is a protective mechanism against bilirubin encephalopathy, as only free bilirubin is regarded as capable of crossing the blood-brain barrier and entering the basal ganglia of the brain.
Bilirubin Conjugation
Unconjugated bilirubin is an organic anion with limited water solubility, and can not be excreted in this form. To begin the excretion process, unconjugated bilirubin is taken up by the hepatocyte wherein it is rendered water soluble by conjugation to glucuronic acid. This conjugation process is catalyzed by the hepatic 1A1 isoform of the enzyme family uridinediphosphoglucuronate glucuronosyltransferase (UGT). Two forms of conjugated bilirubin are recognized: the monoglucuronide fraction, in which the bilirubin molecule combines with one molecule of glucuronic acid, and the diglucuronide fraction, containing two glucuronic acid molecules. It is believed that the same enzyme, UGT1A1, catalyzes both these reactions. The resulting conjugated bilirubin fractions, a form of bilirubin which is excretable, leaves the liver via the bile into the bowel, where much is converted to non-reabsorbable products and excreted in the stool.
Enterohepatic Bilirubin Circulation
In the postnatal period, especially in breastfeeding neonates, the glucuronide component can be cleaved off the conjugated bilirubin molecule by the mucosal enzyme β-glucuronidase. The resulting unconjugated bilirubin can now be reabsorbed, reentering the bilirubin pool and posing an additional load on the hepatocyte. This mechanism, more prevalent in the newborn than in the adult, is known as the enterohepatic circulation of bilirubin and may contribute significantly to the mechanism of physiological jaundice and may be exaggerated in association with decreased enteral transit time [Poland and Odell 1971] .
C. PHYSIOLOGICAL JAUNDICE OF THE NEWBORN

Separation from the Placenta
The process of heme catabolism and thus production of bilirubin actually commences in utero. Prior to delivery, the Fig. (1) . Schema representing the degradation of heme, formation of bilirubin, the conjugation of bilirubin in the liver, and its excretion from the body. From Dennery, P.A.; Seidman, D.S. and Stevenson, D.K. (2001) Neonatal hyperbilirubinemia. New. Engl. J. Med. 344, 581-590, with permission. placenta is responsible for removal of bilirubin and, except for instances of severe intrauterine hemolysis, such as due to Rh isoimmunization, the normal fetus does not usually become jaundiced. However, the liver of the newly delivered neonate may be incapable of sustaining the rate of bilirubin removal that had been maintained by the placenta. As the newborn is relatively polycythemic and excessive RBC break down commences shortly after birth, the bilirubin load increases and, within a few days of delivery, STB concentrations may rise rapidly. For example, in a cohort of term, male neonates with no obvious pathologic risk factors for jaundice, demonstrated a 3.5-fold increase in STB values, from 2.6 ± 0.6 mg/dL (mean ± SD) within the first three hours after delivery, to 8.9 ± 3.0 mg/dL at 52 ± 8 hours post delivery. In the majority of cases, physiological jaundice peaks at about 3 to 4 days, and diminishes towards the end of the first week of life. Under physiological conditions mild imbalance between the bilirubin production and elimination processes should not result in dangerously high STB concentrations developing.
Causes of Physiological Jaundice
Conditions resulting in physiological jaundice may include those increasing bilirubin production, diminishing conjugation or excretion, enhancing the enterohepatic circulation, or a combination of all these mechanisms. Some conditions resulting in increased heme production include high hemoglobin concentrations normally present at the time of delivery, physiologically shortened neonatal RBC lifespan, bruising or cephalhematoma . Maturation of UGT enzyme activity is a function of progressing gestational age [Onishi et al. 1979, Kawade and Onishi 1981] , and prematurity is therefore a major cause of diminished bilirubin conjugation. Indeed, near-term neonates (36-37 weeks gestation) are more prone to neonatal hyperbilirubinemia than counterparts who have completed the full 40 weeks of gestation [Gale et al. 1990] . Infants born prior to this gestational age range are even more susceptible [Soskolne et al. 1996, Maisels and Kring 1998 ]. Diminished activity of UGT may also result from hypoxia, hypothermia and hypothyroidism. The enterohepatic bilirubin circulation has been shown to increase in fasting conditions and may result in augmented bilirubin reabsorption in poorly feeding nursing infants.
Breast Feeding and Neonatal Jaundice
Breast feeding is commonly associated with neonatal hyperbilirubinemia. In a pooled analysis of over 8000 neonates Scheider [1986] showed a threefold and sixfold increase in breastfed infants developing STB concentrations in excess of 12 mg/dL and 15 mg/dL, respectively, compared with those who were formula fed. Full or partial breastfeeding has been found in the majority of neonates rehospitalized for severe hyperbilirubinemia [Soskolne et al. 1996 , Maisels and Kring 1998 , Maisels and Kring 1992 . It is thought that an as yet unidentified factor in breast milk promotes intestinal absorption of bilirubin thus enhancing the enterohepatic circulation of bilirubin [Alonso et al. 1991 , Gartner et al. 1983 . Other factors which have been incriminated in the pathophysiology of breast milk jaundice include high concentrations in breast milk of pregnane-3(α)20(β)-diol, a substance shown to inhibit bilirubin conjugation in utero and to cause increased serum total bilirubin values when administered to newborn infants ]. Human milk β-glucuronidase has been shown by some to facilitate the development of jaundice by hydrolyzing conjugated bilirubin thus allowing for bilirubin absorption from the bowel [Gourley and Arend 1986 ] although others have not been able to demonstrate this finding [La Torre et al. 1999 , Wilson et al. 1992 .
Racial, Familial and Environmental Influences
Racial and environmental influences, possibly due to genetic makeup of the population groups in question, may have an effect on STB concentrations. On the one hand, diminished STB concentrations are found in black neonates compared with white counterparts [Linn et al. 1985] , but on the other, a high incidence of hyperbilirubinemia is encountered in those of East Asian [Horiguchi and Bauer 1975] , Japanese [Maruo 1999 , Fisher et al. 1998 ] or Navajo Indian [Johnson et al. 1986] parentage. Within the same racial group (Greek), Valaes et al. [1969] demonstrated differing incidences of hyperbilirubinemia in population subgroups, which were, for the most part, geographically isolated from each other. Neonatal jaundice frequently occurs in more than one sibling in the same family. Repetition of blood group incompatibility within a family is perhaps to be expected [Plotz 1985 ]. Other familial conditions include glucose-6-phosphate dehydrogenase (G-6-PD) deficiency and hereditary spherocytosis. However, even when obvious icterogeneic factors were corrected for, Khoury et al. [1988] found that the risk of severe jaundice in newborns with one or more prior sibs who were jaundiced in infancy was 12.5 times higher than that of those whose prior sibs were not. This finding suggests that as yet unidentified genetic factors may be contributing to hyperbilirubinemia in certain families or population subgroups.
D.
GENETIC CONTROL OF BILIRUBIN PRODUCTION AND CONJUGATION
Genetic Conditions Increasing Bilirubin Production
Hemolysis
Hemolysis refers to increased breakdown of RBCs, increasing the amount of heme available for degradation, thereby augmenting production of bilirubin. Severe hemolysis is of prime concern to the neonatologist, as kernicterus occurs more frequently in hyperbilirubinemic neonates in the presence of exacerbated hemolysis, than in conditions where hemolysis is absent.
Blood Group Incompatibilities
Rh isoimmunization, once an extremely common cause of severe hemolysis, is nowadays, for the most part, prevented by administration of anti-D globulin to all Rh negative mothers during pregnancy, and postnatally, to those who have delivered an Rh positive infant. As a result, direct Coombs' positive ABO blood group incompatibility is the most common immune cause of hemolysis encountered.
Other isoimmunizations such as anti-c, anti-e, anti-Kell, Duffy and others are less frequent. While blood groups are obviously genetically determined, these conditions are so frequent that comprehensive reviews of the subject exist in many standard textbooks, and will not be discussed in further detail in this overview.
Glucose-6-phosphate Dehydrogenase (G-6-PD) Deficiency
G-6-PD deficiency is one of the most common enzyme deficiencies known and is estimated to affect hundreds of millions of people [WHO Working Group 1989 , Beutler 1994 . Ease of movement and immigration patterns have transformed this condition from one limited, in the past, to areas of south Europe, Africa, the Middle East and Asia, to one which may be encountered virtually in any corner of the globe. One of the most potentially devastating conditions associated with G-6-PD deficiency in the neonate is bilirubin encephalopathy, or kernicterus, as recently reviewed [Valaes 1994 . In the informal Kernicterus Registry [Johnson et al. 2002] at least 22% of neonates with kernicterus had documented G-6-PD deficiency, emphasizing the important role this enzyme deficiency in the pathogenesis of this condition. As G-6-PD deficiency has major public health and clinical implications, and as the condition was described as a paradigm of genes normally associated with benign conditions but sometimes interacting to cause significant disease [Kaplan 1997 ], it will be discussed below in some detail.
Function of G-6-PD
G-6-PD plays a major part in stabilization of the RBC membrane. The enzyme catalyzes the first step in the hexose monophosphate pathway, oxidizing glucose-6-phosphate to 6-phosphogluconolactone, thereby reducing NAPD to NADPH. (Figure 2) . In the RBC, this pathway is the only source of NADPH. NADPH is essential to the RBC for the reduction of oxidized glutathione to reduced glutathione which is itself an essential step in the antioxidative mechanisms against peroxide. The pathway is also instrumental in stimulating catalase, no less important to the RBC's antioxidant defenses. In the absence of G-6-PD, NADPH will not become available to the RBC rendering this cell susceptible to oxidative stress. The damage incurred may manifest as hemolysis. It is important to realize that, although the RBC is the cell primarily affected by the absence of the enzyme, G-6-PD is ubiquitous to many body tissues.
G-6-PD Deficiency and Hemolysis
G-6-PD deficiency is notoriously associated with severe hemolytic episodes, associated with jaundice and anemia, which may occur up to 24-48 hours after exposure to a hemolytic trigger. Classically, these episodes often occur after ingestion of or contact with the fava bean (favism), a staple food in some communities. Vicine and isouramil, substances found in the bean, are thought to trigger the oxidative crisis [Mehta et al. 2000] . These products may be transferred to neonates via breast milk of mothers who had ingested fava ], or transplacentally [Mentzer and Collier 1975, Corchia et al. 1995] . Other identifiable chemical substances which may trigger hemolysis include naphthalene, drugs such as sulphonamides and antimalarials, herbal medicines, henna applications. Beutler [1994] has emphasized the role of infections in the pathogenesis of acute hemolysis. Frequently, however, no identifiable trigger can be found. Severe hemolytic attacks are encountered in adults, as well as in children and neonates.
Genetics of G-6-PD Deficiency
G-6-PD deficiency is an X-linked condition, the gene being one of a cluster on the Xq28, the telemetric band of the long arm of the X chromosome, the other members of the cluster including genes for fragile X, hemophilia A, color vision, and others. The sequence of the 13 exon gene, spanning nearly 20 kb, encoding 515 amino acids and including a promoter region highly enriched in guanine and cytosine residues (GC-rich), a characteristic feature of other housekeeping genes, is known [Persico et al. 1986 , Takizawa et al. 1986 ]. Many mutations have been described, all of which are compatible with some residual enzyme activity [Beutler 1990 , Beutler 1993 , Beutler 1994 . Some examples of those most commonly occurring include G-6-PD A-, found in Africa and southern Europe. This variant is encountered in African Americans in the US, and in descendents of the original Africans who now live in other parts of the Americas. The mutation always encountered, and leading to G-6-PD A, is nt 376 A àG, leading to 126 AsnàAsp. In order for a G-6-PD A individual to become enzyme deficient (G-6-PD A-), one of three additional mutations, on the background of the nt 376G mutation, is necessary. These include nt 202 G àA, 968 T àC and 680 GàT, leading to amino acid substitutions 68 ValàMet, 323 LeuàPro, 227 ArgàLeu. The more severe type, G-6-PD Mediterranean, is found in Mediterranean countries of Southern Europe, the Middle East and India. and in Asia. This mutation is 563 CàT, leading to 188 SeràPhe. Another variant which is widely distributed is G-6-PD Canton, encountered in Asia (1376 GàT, resulting in 459 ArgàLeu). As molecular aspects of G-6-PD deficiency have been comprehensively reviewed, further discussion of this aspect of G-6-PD deficiency is beyond the scope of this paper.
Many screening tests are available which will accurately determine the hemizygous state in males; however, being an X-linked condition, females may be either normal homozygotes, abnormal homozygotes, or heterozygotes. Normally, because of X-inactivation, heterozygotes have two RBC populations: one G-6-PD deficient, and one G-6-PD normal. In individuals in whom the proportions of cells are approximately equal, G-6-PD activity will be intermediate. However, because of non-random X-inactivation, the ratios of RBCs may be unequal, and heterozygotes may, as a result, have either a normal, intermediate or deficient phenotype. Thus, the heterozygote state may be difficult to determine in the absence of PCR based molecular studies [Kaplan et al. 1999, Fairbanks and Fernandez 1969] and many studies of G-6-PD deficiency and G-6-PD deficiency related neonatal jaundice have been limited to male subjects.
The clinician should also be aware that biochemical tests may give a normal result if performed during an acute hemolytic episode, as older RBCs may be destroyed, leaving younger cells, with higher enzyme activity, intact. In these situations G-6-PD testing should be performed several weeks after the acute hemolysis has subsided, when the high proportion of young RBCs will have been corrected. An alternate method is to analyze DNA, obtained from circulating leukocytes, for the specific suspected mutation, as the genotype will not be affected by the presence of young RBCs. The problem of screening for G-6-PD deficiency in the presence of acute hemolysis has been recently comprehensively reviewed [Herschel M and Beutler E 2001] .
G-6-PD Deficiency and Hemolysis
In neonates, the onset of the jaundice may be acute and unpredictable. Hematological indices of hemolysis such as decreasing hemoglobin or hematocrit values, or increasing reticulocyte count, are frequently absent, resulting in the misapprehension that acute hemolysis may not be taking place. However, blood carboxyhemoglobin (COHb) studies, accurately reflecting hemolysis, have been performed in African [Slusher et al. 1994] , Greek [Necheles et al. 1976] and Sephardic Jewish neonates in Israel , and end tidal carbon monoxide studies performed in African American neonates [Kaplan et al. 2004] , all of which have documented increased hemolysis in association with this condition. The hemolysis may sometimes be severe, and exchange transfusion may be the only recourse, in which case its contribution to hyperbilirubinemia is undoubted. Thus, on the one extreme, Slusher et al. [1994] , working in Nigeria, documented significantly higher levels of COHb in G-6-PD deficient neonates compared with controls and even higher values in neonates who developed kernicterus, compared with neonates who were hyperbilirubinemic but did not develop signs of kernicterus. Emphasizing the role played by G-6-PD deficiency in the pathogenesis of kernicterus, these authors note that 75% of the babies with kernicterus were deficient in G-6-PD, compared with only 22% in those who did not progress to kernicterus.
In other instances the hemolysis may be moderate and cannot be directly implicated as the primary etiology of the hyperbilirubinemia. Low-grade hemolysis is often associated with a higher incidence of hyperbilirubinemia, but this hyperbilirubinemia usually responds to phototherapy and exchange transfusion is usually not required. Typical of this variation are Sephardic Jewish neonates in Israel with the G-6-PD Mediterranean mutation and African American neonates, who were studied using COHb corrected for inspired CO (COHbc), and end tidal CO corrected for inspired CO (ETCOc), respectively , Kaplan et al. 2004 . In contrast to the high mortality rate and incidence of kernicterus in the Nigerian neonates (Slusher et al. 1994] , no infant in the latter two series required exchange transfusion or developed kernicterus. , also studying Sephardic Jewish neonates, found that ETCOc values were somewhat increased, but not significantly so, in G-6-PD deficient neonates compared with G-6-PD adequate controls. In another study COHbc values correlated, as expected, with simultaneously drawn third day STB values in G-6-PD normal neonates (r=0.3, p=0.0007) but similar correlation was not documented among the G-6-PD deficient counterparts (r=0.04, p=0.77) . Clearly, in some G-6-PD deficient population groups, increased hemolysis, in and of itself, can be implicated as a primary factor in the development of severe hyperbilirubinemia and kernicterus. In others, in whom hemolysis is only modestly elevated and can not be implicated as a primary icterogenic factor, diminished bilirubin conjugation has been shown to be of major importance in the pathogenesis of the jaundice, as described in a subsequent section.
G-6-PD Heterozygosity and Neonatal Jaundice
Few studies have investigated the role of G-6-PD heterozygosity in the pathogenesis of neonatal bilirubinemia using molecular DNA methods to determine the genotype. Huang et al. [1996] identified 43 heterozygotes of 50 G-6-PD-deficient female Taiwanese neonates, in whom the nucleotide 1376 (G>T) mutation was predominant. In contrast to G-6-PD-deficient males of that population group, in whom the incidence of hyperbilirubinemia, defined as peak serum total bilirubin > 15.0 mg/dL, was significantly greater than controls (24.0% vs. 10.8%, p<0.001), the G-6-PD-deficient females did not have a greater incidence of hyperbilirubinemia than controls (8.0% vs. 5.9%, p=0.56). These authors attributed the lack of increased incidence of neonatal hyperbilirubinemia to the moderate G-6-PD activity still available in the heterozygotes. In contrast is the study of Kaplan et al. [1999] who studied the role of G-6-PD deficiency in determining neonatal hyperbilirubinemia in a cohort of Sephardic Jewish females with G-6-PD Mediterranean. The risk of developing serum total bilirubin 15 mg/dL was greater in both G-6-PD heterozygotes (12/54 patients, 22%; relative risk: 2.26; 95% CI: 1.07-4.80) and deficient homozygotes (5/19 patients, 26.3%; relative risk: 2.68; 95% CI: 1.05-6.90), than normal homozygotes (11/112 patients, 9.8%). Similarly, third day serum bilirubin testing in this study demonstrated that G-6-PD heterozygotes and deficient homozygotes had serum total bilirubin values that were significantly higher than those of the G-6-PD normal homozygote controls (11.3 ± 3.7 mg/dL and 12.0 ± 3.0 mg/dL respectively, vs. 9.4 ± 3.4 mg/dL, p<0.01). It was therefore surprising that COHbc values were increased significantly only in the G-6-PD deficient homozygotes (0.74 ± 0.14%, p=0.02), but were intermediate, and not significantly higher in the heterozygotes (0.69 ± 0.19%), compared with the normal homozygotes (0.63 ± 0.19%). As will be shown in a subsequent section, presence of UGT promoter polymorphism is a major factor in the pathogenesis of hyperbilirubinemia in the G-6-PD deficient state. The contrasting results of this report and that of Huang et al. may be due to the different G-6-PD mutation, paucity of UGT 1A1 promoter polymorphism in the Chinese population , and additional genetic or environmental factors. Adding support to the concept of G-6-PD heterozygosity contributing to neonatal disease process are case reports of severe hemolysis and hyperbilirubinemia in two female Sephardic Jewish G-6-PD heterozygotes and an African American heterozygote (G-6-PD A+/A-) [Herschel et al. 2002] , all of who had molecular confirmation of their heterozygous state.
It was previously thought that heterozygotes had sufficient enzyme activity to protect them from the dangers of G-6-PD deficiency [WHO Working Committee 1989] . However, the above, more recent reports, suggest that, in the absence of a rapid molecular testing method, female neonates from a high risk population group should be closely watched for the development of jaundice, even though their G-6-PD biochemical testing may be normal.
Pyruvate Kinase Deficiency
Pyruvate kinase catalyzes the conversion of phosphoenolpyruvate to pyruvate and the formation of adenosine triphosphate from adenosine diphosphate in the Embden-Meyerhof pathway. Pyruvate kinase deficiency results in a lack of adenosine triphosphate for RBC metabolism and as a result, anemia, reticulocytosis and severe jaundice. This RBC enzyme defect is much less frequently encountered than G-6-PD deficiency, and inherited as an autosomal recessive condition [Mentzer 1998 ]. Four mutations are commonly associated with this condition: c.1456 CàT (1456T), c.1468 CàT (1468T), c.1484 CàT (1484T), and c.1529 GàA (1529A) [Beutler and Gelbart 2000] . Among white patients the frequency of the 1456T mutation was 3.50 x 10 -3 while that of the 1529A mutation was 2.03 x 10 -3 . Among African Americans the frequency of the 1456T mutation was 3.90 x 10 -3 , while 1468T was found in Asians at a frequency of 7.94 x 10 -3 . Based on the gene frequency of the 1529A mutation in the white population, the prevalence of pyruvate kinase deficiency was estimated as 51 cases per million white population.
In the newborn, severe hemolysis with hyperbilirubinemia requiring exchange transfusion may occur, and kernicterus has been described. Diagnosis is determined by enzyme analysis, which should be performed in cases of hemolysis and hyperbilirubinemia not associated with a positive direct Coombs' test or spherocytosis.
Hereditary Spherocytosis
Of the hereditary RBC membrane defects which may lead to acute hemolysis and hyperbilirubinemia in the newborn, hereditary spherocytosis is probably the most common [Gallagher et al. 1998 ]. An association with kernicterus has been recognized for many years. Hereditary spherocytosis is also one of the few causes of hyperbilirubinemia which does not resolve in the neonatal period. This condition may be inherited both in an autosomal dominant and recessive fashion, and frequently there will be a history of acute hyperbilirubinemia in a sibling. It is thought that protein defects in the RBC membrane leave microscopic patches of the lipid bilayer inner surface bare of proteins, at which points microvesiculization occurs. Osmotically fragile RBCs are trapped in the spleen, the microvesicles aspirated by macrophages, and the cell destroyed. This hemolysis may result in jaundice, anemia and splenomegaly. The diagnosis can be made microscopically, with confirmation by the osmotic fragility test. The latter test may be especially important in differentiating babies with hereditary spherocytosis from those with direct Coombs' positive ABO isoimmunization, a condition which may also result in microspherocytosis.
Hereditary spherocytosis is frequently associated with neonatal hyperbilirubinemia and the need for phototherapy is high: of 178 affected Italian term, predominantly breast fed newborns, 112 (63%) developed neonatal hyperbilirubinemia requiring phototherapy. The incidence of hyperbilirubinemia was even higher in those who also had a genetic variation in the promoter of the bilirubin UGT1A1 gene, as will be discussed in a subsequent section ]. Treatment comprises intense phototherapy with resort to exchange transfusion in cases unresponsive to light therapy. Splenectomy is frequently necessary during childhood in order to control the anemia resulting from ongoing hemolysis. Mutations of at least 5 genes which cause hereditary spherocytosis have been recognized including ANK 1 which encodes ankyrin 1, EPB3 which encodes protein AE1 or band 3, SPTB which encodes the spectrin β-chain, ELB42 which encodes protein 4.2, and SPTA1 which encodes the spectrin α-chain.
Other RBC membrane defects such as elliptocytosis and ovalocytosis are rare and beyond the scope of this review.
Heme Oxygenase
The clinical significance of heme oxygenase (HO) is gaining importance because of development of metalloporphyrins, a group of pharmacological preparations capable of inhibiting the enzyme thereby limiting the production of biliverdin and bilirubin from heme (see discussion below). Multiple body functions are attributable to HO; however, its primary function relevant to the purpose of this discussion is its rate-limiting effect on the catalyzation of the conversion process of heme into biliverdin. In addition to heme, by-products of the reaction, carbon monoxide, a neurotransmitter and vasodilator, and iron, capable of gene regulation, are also produced (Fig. 1) . Furthermore, the bilirubin produced has also been shown to have protective antioxidant properties [Verma et al. 1993 , Zakhary et al. 1996 , Haile et al. 1992 , Stocker et al. 1987 , Dennery et al. 1995 ]. The enzyme consists of three different isoforms, HO-1, HO-2 and the most recently discovered HO-3, although most knowledge is available for the HO-1 isoform. It is thought that HO-1 plays the predominant role in the degradation of heme to biliverdin [Kanai et al. 2003 ]. As expression of the HO-1 gene may be induced as a response to oxidative stress, this gene has been termed a stress response gene [Applegate et al. 1991] . Additional transcription factors such as glucocorticoids, activator protein-1 and nuclear factor kappaB, bound to the gene promoter, may enhance HO-1 gene expression thereby stimulating heme catabolism and bilirubin production. HO-2 also plays a role as a heme regulator, but differs from HO-1 in that, while HO-1 is produced ubiquitously, HO-2 production is limited to brain and testis. HO-2 is unresponsive to the factors capable of stimulating HO-1.
The HO-1 gene contains 5 exons. Distal enhancer regions 1 and 2, and the proximal enhancer, situated upstream of the promoter, contain many transcription factor binding regions [Dennery 2001 ]. The HO-1 gene has a polymorphic (GT) n dinucleotide repeat sequence in its promoter. Gene transcription and hence expression of the HO-1 enzyme is modulated by this sequence, its activity being inversely related to the number of (GT) repeats. [Okinaga et al. 1996 , Yamada et al. 2000 . The distribution of the number of (GT) repeats may vary between population groups. Kamai et al.
[2003] compared Japanese (n=122) and German (n=89) subjects by dividing the populations into three groups, based on the number of (GT) repeats: < 26 alleles, 27-32 alleles, and > 33 alleles. The distribution among Japanese was 45.5%, 37.7% and 18.8%, respectively, while corresponding percentages for Germans were 32%, 63.5% and 4.5%. The Japanese had a significantly greater < 26 and > 33 allele distribution than the Germans (p=0.006 and p<0.001 respectively, and fewer of the intermediate alleles than did the Germans (p=0.001).
Polymorphisms of the genes encoding HO-1 have not been described, although in one case of a 6 year old boy, abnormal features including growth retardation, hemolytic anemia, low bilirubin, abnormal coagulation/fibrinolysis system, and renal and hepatic iron deposition, were attributed to absence of functional HO-1 activity. Sequence analysis of the patient's HO-1 gene demonstrated complete loss of exon-2 of the maternal allele and a two-nucleotide deletion within exon 3 of the paternal allele. [Yachie et al. 1999] .
In an attempt to explain the high incidence of neonatal hyperbilirubinemia in Japanese neonates Kanai et al. [2003] sequenced the promoter and coding areas of the HO-1 gene of 30 Japanese infants who had undergone phototherapy, and compared them with 119 subjects who had not required phototherapy. Neonates with polymorphisms of the UGT gene associated with icterogenicity including the G71R or (TA) 7 mutations were removed from the analysis. No mutations were detected among the remaining neonates who had required phototherapy, either in the HO-1 promoter or coding regions. The promoter (GT) n sequence was further analyzed into three subclasses, according to the number of (GT) repeats. No difference in the distribution of allele frequency of these subclasses was detected when phototherapy-requiring Japanese neonates were compared with those who had not required treatment. Although there was a significant difference in allele frequencies of the (GT) n sequence and its subclasses when the Japanese neonates were compared with German counterparts, no correlation between this polymorphism and the development of neonatal jaundice could be determined. It therefore appears that the contribution of increased hemolysis to the development of neonatal jaundice in this population cannot be attributed to mutations of the HO-1 gene.
Reduction of Biliverdin to Bilirubin
Biliverdin is reduced to bilirubin by the enzyme biliverdin reductase. In the fetus, a beta variant of the enzyme functions to produce bilirubin IXβ, an isomer which, unlike the adult type bilirubin IXα, is water soluble and readily excretable without the need to undergo the conjugation. For reasons not understood, at birth, bilirubin reduction changes from the beta to alpha form, as enzyme activity is shifted from that of bilirubin IXβ reductase to bilirubin IXα reductase. This change to the adult bilirubin isomer type, as well as inherent immaturity of the UGT enzyme activity, are probably important contributing factors to the newborn's difficulty in eliminating bilirubin. Rat studies suggest that biliverdin may play a regulatory role in bilirubin production by inhibiting HO and bilirubin reductase by a negative feedback loop. The mechanism of this process may be biliverdin occupying the heme binding site on heme oxygenase molecule, thus hindering the access of the substrate to the enzyme's catalytic site [Kutty and Maines 1984] .
The gene encoding biliverdin reductase, consisting of five exons and four introns, lacks a conventional TATA box [McCoubrey et al. 1995] . Genetic polymorphisms of this gene have not been described and the contribution, if any, to abnormalities in the metabolism of biliverdin to bilirubin, have not been elucidated.
Uptake of Bilirubin into the Hepatocyte
Unconjugated bilirubin is taken up from the hepatic sinusoids and crosses the hepatocyte membrane to enter into that cell. This process is facilitated by a carrier molecule, organic anion-transporting polypeptide-2 (OATP2, gene SLC21A6). Human OATP2 may play an important role in the metabolism of bilirubin and in the prevention of hyperbilirubinemia by facilitating the selective entry of bilirubin into hepatocytes (Cui et al. 2001) . Until recently, mutations of the OATP-2 or SLC21A6 gene, with the potential of interfering with function of the transport protein, had not been identified. However, Michalski et al. [2002] have identified a naturally occurring mutation in the SLC21A6 gene leading to impaired maturation of the protein with reduced membrane localization and abolished transport function. Recently, a number of single-nucleotide polymorphisms have been identified in the SLC21A6 gene, some of which are associated with an altered in vitro transport capability [Tirona et al. 2001] . Using pravastatin, a drug taken up by the liver through the organic aniontransporting polypeptide, as a selective probe drug, Nishizato et al. [2003] determined that certain commonly occurring single nucleotide polymorphisms of this gene, such as T521C (Val174Ala) are likely to be associated with altered pravastatin pharmacokinetics. Much earlier, in adults with clinical features of Gilbert's syndrome (prior to discovery of the molecular mutation associated with this condition) Berk and Blascke [1972] documented diminished clearance of bromsulphthalein (BSP) and indocyanine green dyes. This finding was thought to represent, at least in part, diminished bilirubin uptake into the hepatocyte.
In an attempt to determine the reason that some individuals homozygous for an additional TA sequence in the TATAA box of the UGT gene promoter develop mild jaundice attributable to Gilbert's syndrome, while others do not, Persico et al. [2001] demonstrated diminished bromsulpthalein uptake in those individuals who were icteric. These authors concluded that the lower BSP uptake in Gilbert's syndrome is probably caused by an independent, genetically determined defect in hepatic transport mechanisms, shared by BSP and bilirubin, that are necessary for phenotypic expression of GS. Although this mechanism has not been studied in neonates, it does seem possible that, in addition to increased hemolysis and diminished bilirubin conjugation, in some neonates homozygous for the variant (TA) 7 UGT promoter, diminished bilirubin uptake may play a role in the pathophysiology of neonatal hyperbilirubinemia.
Once within the hepatocyte, bilirubin is once again bound, this time to the carrier protein glutathione Stransferase (GST), also known as ligandin or Y-protein. Uptake of bilirubin increases proportionally to the concentration of ligandin within the hepatocyte [Wolkoff et al. 1979] . These cytosolic proteins are of importance in diminishing reflux of unconjugated and conjugated bilirubin back into the plasma. Levi et al. [1970] documented low hepatic ligandin levels in newborn monkey liver while adult values were attained within 1 to 2 weeks. The human newborn is generally deficient in ligandin, a factor which may contribute to diminished ability to retain bilirubin within the hepatocyte. Although several polymorphisms of GST expression occur in humans there is no evidence that deficiency of ligandin beyond the lower limits of the physiological range is involved in the pathogenesis of neonatal hyperbilirubinemia [Hansen 2000 ]. GST may have therapeutic implications, however, as pharmacologic agents, such as phenobarbital, function by increasing the concentration of ligandin within the hepatocyte [Wolkoff 1979 ].
Genetics of Dimished Bilirubin Conjugation
Perhaps one of the most important advances in our understanding of the genomics of bilirubin metabolism is the elucidation of the UGT gene encoding the bilirubin conjugating enzyme, UDP-glucuronosyltransferase 1A1 (UGT). Several recent reviews of this subject exist [Strassburg and Manns 2000 , Burchell and Hume 1999 , Mackenzie et al. 2000 , King et al. 2000 , Bosma 2003 , Mackenzie et al. 1997 , Sampietro and Iolascon 1999 , Tukey and Strassburg 2000 , Clarke et al. 1997 ; this section will therefore comprise a short overview so as to allow the reader to fully comprehend mutations of this gene, and interactions of these mutations with additional icterogenic factors, genetic or environmental, in the mechanism of jaundice.
The UGT Gene
The UGT gene is a superfamily of genes. Their function is to encode a biochemical reaction leading to the conjugation of glucuronic acid to certain target substrates in order to facilitate their elimination from the body. The UGT2 genes are located on chromosome 4q13 and 4q28. The enzymes encoded by this family preferentially glucuronidate endobiotic substances including steroids and bile acids and while of physiological and pharmacological importance, are of little relevance to bilirubin metabolism.
Of major importance to the conjugation and elimination of bilirubin is the UGT1A1 gene, which has been mapped to chromosome 2q37 [van Es et al. 1993] . UGT 1A1, cloned by Ritter et al. in 1991 [Ritter et al. 1991 encodes isoform 1A1 of the UGT enzyme, which is of paramount importance in the conjugation of bilirubin. The UGT1A gene is 218 kb long [Gong et al. 2001] . The gene consists of 4 common exons (exons 2,3,4 and 5) and 13 variable exons, although only 9 of these code for functional proteins (4 pseudogenes are present). (Figure 3) . Of the remaining 9 exons, only variable exon A1 is of any importance regarding bilirubin conjugation; the remaining exons play a role in the detoxification of a diverse range of chemical substances. The variable exons function in conjunction with the common exons 2 to 5: in response to a specific signal, transcription processing splices mRNA from the single variable exons to the common exons. This process provides a template for the synthesis of an individual enzyme isoform.
Upstream of each variable exon is a regulatory 5' noncoding promoter area. The proximal part of these promoters contains a TATAA box sequence of nucleic acids, which are important for the transcription process by RNA polymerase II. Mutations of variable exon A1, its promoter, or the common exons 2-5, may result in deficiencies of bilirubin conjugation. Polymorphisms of the non-coding promoter area affect bilirubin conjugation by diminishing enzyme expression, while mutations of the gene coding area may affect enzyme function by altering the structure of the enzyme molecule As they interact with the variable exons, mutations of common exons 2-5 may also result in deficient elimination of the chemical substances encoded by variable exons 2-13.
Abnormalities of UGT1A1 Leading to Hyperbilirubinemia
Basically, three clinical entities may arise as a result of mutations of these gene areas: Gilbert's syndrome and CriglerNajjar (C-N) syndromes types 1 and 2. Interactions with additional icterogenic factors, and compound heterozygosities, however, may function to expand the effects of these mutations and broaden their clinical implications. While the Crigler-Najjar syndromes are the most serious of these disease processes, these conditions are fortunately relatively rare. Gilbert's syndrome, on the other hand, while of a less serious nature clinically in and of itself, is far more commonly encountered and has major implications in the pathogenesis of adult bilirubinemia and neonatal hyperbilirubinemia. For these reasons, this condition will bear the major emphasis of this discussion.
Gilbert's Syndrome
Clinical Aspects
Gilbert's syndrome is a common, benign condition frequently encountered in healthy adults [Radu and Atzmon 2001 , Strassburg and Manns 2000 , Burchell and Hume 1999 , Mackenzie et al. 2000 , King et al. 2000 , Bosma 2003 , Mackenzie et al. 1997 , Sampietro and Iolascon 1999 , Tukey and Strassburg 2000 , Clarke et al. 1997 . The syndrome, which affects about 6% of the adult population, is a benign, inherited condition, usually first diagnosed during adolescence. The condition is characterized by mild, indirect bilirubinemia which typically increases with fasting. In some individuals, mildly increased STB concentrations may be noted on routine serum biochemical analysis, giving rise to fears that an individual may be suffering from liver disease. However, there is usually no additional evidence of liver dysfunction, and normal serum liver enzyme values are usually encountered. Classically, there is no overt evidence of hemolysis [Clarke et al. 1997, Burchell and Hume 1999] . Clinically, the diagnosis is one of exclusion.
Gilbert's Syndrome in Caucasian Populations
TA Promoter Polymorphism
In Western populations, the most common genetic polymorphism encountered in association with Gilbert's syndrome is that of an additional TA insertion in the TATAA box of the UGT 1A1 promoter, identified as UGT1A1*28. The usual (wild type) promoter allele comprises a sequence of 6 (TA) nucleotide insertions and wild-type individuals are homozygous for a (TA) 6 TAA/(TA) 6 TAA (6/6) promoter genotype. (Fig. 3 ) Some individuals have a (TA) 7 TAA allele, also termed UGT1A1*28. Homozygosity for UGT1A1*28 (7/7), is associated with Gilbert's syndrome, although not all Fig. (3) . The human UGT1 gene locus: Schematic representation of the genomic structure of the UGT1 gene complex. Variable exon 1A1 and common exons 2-5 of the gene complex have been identified as those sites encoding the bilirubin conjugating enzyme, UDPglucuronoslytransferase. Variable exons 1A2 to 1A13 do not participate in bilirubin metabolism. Genetic mutations associated with absent or decreased enzyme activity, that cause deficiencies of bilirubin conjugation, have been localized to these variable exon 1A1, its promoter, or the common exons 2 to 5. The upper section of the diagram demonstrates the possible exon 1A1 promoter TATAA box genotypes: closed boxes represent usually encountered promoter genotypes, while dotted boxes represent rare forms. individuals homozygous for the 7/7 promoter mutation manifest clinical signs of this condition [Bosma et al. 1995 , Monaghan et al. 1996 . This suggests that additional factors, for example male sex, may interact with the genotype to determine the phenotype. Another factor could be the independent, genetically determined defect of hepatic transport determining bilirubin uptake, described above [Persico et al. 2001] . Heterozygotes have one allele each of the wild type and variant promoter (6/7). Infrequently, individuals have been demonstrated to have a (TA) 5 or (TA) 8 promoter [Beutler et al. 1998 ].
TA Promoter Polymorphism and Diminished Bilirubin Conjugation
The addition of an extra TA sequence lessens the affinity of TATAA-binding protein to the TATAA box and as a result, promoter activity, reflected by the production of firefly luciferase, the reporter product, decreases progressively with each additional (TA) sequence [Bosma et al. 1995 , Beutler et al. 1998 ]. (Figure 4) . Correspondingly, the (TA) 5 sequence was associated with promoter activity which was greater than the wild type (TA) 6 sequence. Because the gene coding area in these individuals is not affected, the UGT enzyme production may be reduced to as much as 30% of normal activity; however, the enzyme molecule synthesized will be structurally normal. This reduced enzyme expression results in diminished bilirubin conjugation and as a result, increased STB concentrations.
In Caucasian populations, the frequency of the UGT1A1*28 allele is between 35 and 40%, with homozygosity for this mutation found in 11-16% [Bosma 2003 ]. In Asian populations, frequency of the UGT1A1*28 allele is less frequently encountered , Sato et al. 1996 , Ando et al. 1998 ] and clinical manifestations of Gilbert syndrome may be accounted for by a different, coding area mutation, G71R (below).
UGT promoter polymorphism, primarily in its homozygous (7/7) form, has been demonstrated to be associated with significantly higher STB values in both adults and neonates, compared with wild type 6/6 controls (Bosma et al. 1995 , Monaghan et al. 1996 , Roy Chowdhury et al. 2002 , Skarke et al. 2004 . (Figure 5) . Supportive of the concept that the mechanism for this bilirubinemia is diminished bilirubin conjugation includes the demonstration that UGT1A1 enzyme activity was lowest in hepatic tissue from homozygotes for the variant 7/7 UGT promoter (749 nmol/g liver/h; p<0.005) and intermediate in 6/7 heterozygotes (985 nmol/g liver/h; p<0.05), compared with normal 6/6 homozygotes (1565 nmol/g liver/h) [Raijmakers et al. 2000] . The differences in enzyme activity between the 6/7 and the 7/7 genotype groups were not significantly different. Additional evidence was supplied by studies of serum total conjugated bilirubin. Conjugated bilirubin effluxes from the hepatocyte and its measurement therefore can be used to reflect bilirubin conjugation ). As can be seen in figure 5, total conjugated bilirubin values expressed as a percentage of serum total bilirubin (median, interquartile range) were significantly lower in neonatal 7/7 homozygotes (0.48 [0.24-0.78] µmol/L) than 6/6 counterparts (0.81 [0.47-1.27] µmol/L; P = .035), with a trend to being lower than 6/7 heterozygotes (0.74 [0.48-1.32] µmol/L, P = .06). . Fig. (4) . UGT promoter activity (mean ± SE) with five through nine (TA) sequence repeats. The production of luciferase, the reporter product, decreases progressively as the number of repeats increases. The (TA) 9 variant, made by mutagenesis, has not been encountered in nature and has similar activity to the (TA) 8 form. The solid bar is the wild type (TA) 6. From Gelbart, T. and Demina, A. (1998) Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: A balanced polymorphism for regulation of bilirubin metabolism. Proc. Natl. Acad. Sci. USA. 95, 8170-8174, with permission. th and 25 th percentiles, respectively. Serum total bilirubin and blood carboxyhemoglobin values were significantly higher in the 7/7 homozygotes than in both 6/6 homozygotes and 6/7 heterozygotes. Total conjugated bilirubin was significantly lower in the 7/7 homozygotes than the 6/6 homozygotes, while the production-conjugation index was significantly higher in the 7/7 promoter group than in those with the 6/6 or 6/7 promoter. From Kaplan, M.; Hammerman, C.; Rubaltelli, Rare individuals with (TA) 5 or (TA) 8 sequences have been identified primarily in those of African origin [Beutler et al. 1998 , Innocenti et al. 2002 , although there have been reports of these sequences in people of European ancestry (Te Morsche et al., 2001 , Innocenti et al. 2002 , Iolascon et al. 2000 , Skarke et al. 2004 .
Population studies have shown that African-American neonates have lower serum bilirubin levels, and Asian infants higher, than their Caucasian counterparts. Beutler et al. [1998] therefore presumed that the less active (TA) 7 mutation with resultant diminished bilirubin conjugation would be less prevalent in individuals of African extraction while the more active (TA) 6 variation (improved conjugation) would be more frequently encountered. In fact, while UGT promoter activity consistently showed an inverse relationship to the number of (TA) repeats in each of the three population groups studied, contrary to expectations, the [TA] 7 variety was more common in people of African, and less common in people of Asian origin, than in Caucasians. From this study it is apparent that, while within an ethnic group there is a strong correlation between the promoter repeat number, its activity, and serum bilirubin levels, the relationship may not always hold out between ethnic groups. This apparent inconsistency may be due to the fact that the etiology of jaundice is multifactorial, with many genetic and environmental factors playing a part.
TA Promoter Polymorphism and Increased Heme Catabolism
Although Gilbert's syndrome is not associated with evidence of overt hemolysis a shortened red cell life span has been found in some affected individuals [Foulk et al. 1959 , Arias 1962 , Pitcher and Williams 1963 (2 articles) Berk and Blaschke 1972 , Besinger et al. 1973 , Okolicsany et al. 1978 . However, the subjects in these studies were preselected because of clinically apparent Gilbert's syndrome, i.e mildly visible jaundice or incidentally detected elevated serum bilirubin levels. The question of whether UGT 1A1 promoter polymorphism has an effect on heme catabolism, in addition to that of diminished bilirubin conjugation, was recently definitively answered. identified a neonatal cohort according to UGT promoter polymorphism, rather than the presence of bilirubinemia, thereby avoiding selection bias (Fig. 5) . Expectedly, serum total bilirubin conjugates were significantly lower in the homozygotic 7/7 group than in 6/7 heterozygote or 6/6 homozygote counterparts. What was surprising was that blood carboxyhemoglobin values corrected for inspired CO (COHbc), an accurate index of heme catabolism , were significantly higher in the UGT 7/7 homozygotes, compared with controls of both 6/7 and 6/6 promoter genotypes. As a result of increased hemolysis as well as diminished bilirubin conjugation the bilirubin production-conjugation index (COHbc divided by total conjugated bilirubin) was significantly higher in those homozygous for the 7/7 UGT promoter genotype than those with the 6/6 wild type or 6/7 heterozygotes. It is now apparent that UGT1A1 promoter polymorphism may influence serum total bilirubin values by both increasing heme catabolism as well as diminishing bilirubin conjugation, and also possibly influencing bilirubin uptake into the hepatocyte.
TA Promoter Polymorphism and Neonatal Jaundice
It had been suggested for many years that some infants with indirect hyperbilirubinemia could be manifesting the effects of Gilbert's syndrome. However, this concept could not be fully studied until the association between the condition and its genetic mechanism had been established. Bancroft et al. [1998] , using a transcutaneous jaundice meter to evaluate jaundice, found that homozygosity for the variant 7/7 UGT gene promoter did not necessarily result in higher peak jaundice index levels or in hyperbilirubinemia, but did cause a significantly greater increase in the index during the first two days of life than in controls. Roy-Chowdhury et al. [2002] in a study of predominantly breast-feeding Greek neonates in whom direct Coombs' positivity, ABO incompatibility and glucose-6-phosphate dehydrogenase (G-6-PD) deficiency had been excluded, found significantly higher STB values at 96 hours of life in those homozygous for the variant 7/7 UGT promoter (10.2 ± 1.4 mg/dL) and intermediate values in 6/7 heterozygotes (8.9 ± 3.1 mg/dL) compared with homozygous normal 6/6 controls (7.0 ± 3.2 mg/dL, p=0.005). In this patient group, 7/7 UGT promoter homozygosity was not associated with hyperbilirubinemia. Laforgia et al. [2002] found a significantly higher frequency of homozygosity for the variant 7/7 promoter in neonates (hemolytic conditions excluded) with STB concentrations > 13.0 mg/dL compared with controls whose STB values did not exceed that concentration (26.8% vs. 12.2%, p<0.05). Peak STB values did not differ according to promoter genotype. In a study of Turkish neonates by Ulgenalp et al. [2003] , the 7/7 UGT promoter variation was encountered in 13% of those whose serum bilirubin concentrations exceeded 12.9 mg/dL, compared with 6% of the control population. This difference was not statistically significant. Mean serum bilirubin values of the jaundiced neonates were similar between the 7/7, 6/7 and 6/6 genotypes, although no information is provided regarding the timing or number of bilirubin tests included in these means. From these studies, it is apparent that, in the absence of additional icterogenic factors, 7/7 UGT promoter polymorphism contributes only modestly to the mechanism of neonatal jaundice.
Interaction of TA Promoter Polymorphism and G-6-PD Deficiency
Perhaps the most dramatic contribution of UGT (TA) promoter polymorphism to the pathogenesis of neonatal jaundice was demonstrated by Kaplan et al. [1997] in Israeli G-6-PD (Mediterranean) deficient neonates. In line with the above mentioned studies, among the G-6-PD normal neonates, no significant difference in the incidence of hyperbilirubinemia, defined as STB >15mg/dL, was demonstrated between neonates bearing the three different UGT 1A1 promoter genotypes. (Figure 6 ). In contrast, in G-6-PD deficient counterparts, superimposition of the variant UGT promoter resulted in a significant increase in the incidence of hyperbilirubinemia: STB levels >15mg/dL occurred in 10% of G6PD deficient infants homozygous (6/6) for the normal promoter, 35% of 6/7 heterozygotes (p<0.0001) and in 50% of 7/7 homozygotes (p=0.02) -an allele dose-dependent response. Interestingly, neonates who were G6PD deficient, but homozygous for the normal (6/6) UGT promoter did not have a higher incidence of hyperbilirubinemia than G-6-PD-normal controls of the same UGT promoter genotype. Therefore, neither G-6-PD deficiency individually, nor presence of the variant UGT1 promoter gene in its 6/7 or 7/7 forms but in the absence of G-6-PD deficiency, could be designated risk factors for neonatal hyperbilirubinemia. The authors concluded that the development of jaundice was dependent on an interaction between these two factors.
In Italian G-6-PD deficient neonates , Galanello et al. 1999 homozygosity for the variant 7/7 promoter apparently did not increase the risk of hyperbilirubinemia as it did in Israeli counterparts [Kaplan et al. 1997] . This is surprising as, in Italian adults, homozygosity for the variant 7/7 UGT promoter was reported as a major determinant of increased serum bilirubin levels associated with G-6-PD deficiency [Sampietro et al. 1997] . The discrepancy between the Israeli and Italian neonates could possibly be explained by genetic differences between the populations studied, or lack of uniformity in definitions of hyperbilirubinemia used by the researchers. However, while the Israeli study was population based, in the Italian study, analysis was performed only among those neonates who actually developed hyperbilirubinemia. When data of the Israeli neonates were reanalyzed in the same way as the Italian neonates had been studied, the effect of UGT promoter polymorphism became masked . It is therefore also possible that the lack of effect of the variant 7/7 UGT promoter among the Italian neonatal population is only apparent, the result of a non-population based statistical methodology .
Other interactions between TA promoter polymorphism and additional conditions, leading to increased serum bilirubin concentrations, have been described by Kalotychou et al. [2003] in Greek patients with thalassemia intermedia and sickle cell disease, by Tzetis et al. [2001] and Passon et al. [2001] who reported higher serum bilirubin values associated with 7/7 homozygosity in patients with betathalassemia and sickle cell anemia, respectively, and Galanello et al. [1997] and Sampietro et al. [1997] in Italian individuals with heterozygous β-thalassemia.
UGT Promoter Polymorphism and Prolonged Neonatal Jaundice
Studies of the relationship of UGT promoter polymorphism to prolonged jaundice have not yielded consistent results. In Scotland, it was found that 31% of neonates (almost all of whom were breast feeding) with prolonged jaundice (STB levels >5.8mg/dL >14 days of life) were homozygous for the 7/7 Gilbert's syndrome promoter genotype compared with only 6% of a control group with acute jaundice (p<0.05) [Monaghan et al. 1999] ). On the other hand, in a Turkish population, homozygosity for the 7/7 promoter genotype was encountered in only 8% of those with prolonged jaundice, compared with 6% of controls (Ulgenalp et al. 2003) .
Additional Gene Interactions of UGT Promoter Polymorphism Leading to Neonatal Hyperbilirubinemia
By itself, hereditary spherocytosis can produce hemolysis and hyperbilirubinemia in neonates. In a population of 178 newborns with this condition, 63% developed hyperbilirubinemia sufficient to require phototherapy. Twenty-nine of these were homozygous for the 7/7 UGT promoter mutation, of whom all but one required phototherapy. ]. In contrast to the crucial role played by presence of the variant UGT promoter in G-6-PD deficiency, hereditary spherocytosis per se is sufficient to result in neonatal hyperbilribinemia even in neonates who are homozygous for the normal UGT gene. This is probably due to such a high degree of hemolysis, that the conjugative capacity of the neonatal liver becomes overwhelmed.
Several studies have found no increase in the incidence of hyperbilirubinemia in direct Coombs' negative blood group A or B infants of group O mothers [Ozolek et al. 1994 , Leistikow 1995 . Similarly, did not find a significantly increased incidence of hyperbilirubinemia (STB >15.0 mg/dL) when direct Coombs' negative ABO -incompatible and -compatible neonatal cohorts were compared. However, among the subset of ABO incompatible neonates of that same cohort who were also homozygous for the variant 7/7 UGT promoter the incidence of hyperbilirubinemia became significantly greater than in 6/6 homozygote counterparts (43% vs. 0%, p=0.02).
It is now evident that, in the absence of additional icterogenic factors, presence of the variant 7/7 UGT gene promoter may be associated with higher STB levels, but does not necessarily lead to significant hyperbilirubinemia. When combined with factors that increase bilirubin production, however, homozygosity for 7/7 UGT promoter polymorphisms, and sometimes even 6/7 heterozygosity, may potentiate the risk of neonates developing high STB levels. The basic mechanism of the hyperbilirubinemia is probably a combination of increased hemolysis, however slight, and diminished bilirubin conjugation, resulting in loss of equilibrium between these two processes with bilirubin production outweighing bilirubin clearance.
Gilbert's Syndrome in Asian Populations
In contrast to the high frequency of UGT 1A1 promoter polymorphism in Caucasian populations, TATAA promoter variations are rare in Asian populations. encountered only 1 of 218 non-hyperbilirubinemic Taiwanese neonates who was homozygous for the 7/7 TA UGT promoter. The allele frequency for the (TA) 7 sequence was 0.124. Similarly, Hsieh et al. [2001] determined a 0.1 frequency for the variant (TA) 7 gene promoter. Gilbert's syndrome in Asians appears to result from missense mutations in the coding area of the UGT 1A1 gene. The most common of these is a G>A transition at nucleotide 211, which causes arginine to replace glycine at position 71, of the corresponding protein product [Maruo et al. 1999 , Akaba   Fig. (6) . Incidence of hyperbilirubinemia, defined as serum total bilirubin concentration >15.0 mg/dL (256 µmol/L), for G-6-PD-deficient and control neonates, stratified for the three promoter genotypes, A(TA) 6 TAA/A(TA) 6 TAA, A(TA) 6 TAA/A(TA) 7 TAA, A(TA) 7 TAA/A(TA) 7 TAA, respectively, of the gene encoding the bilirubin conjugating enzyme UDP glucuronosyltransferase 1A1. From Kaplan, M.; Renbaum, P.; Levi-Lahad, E.; Lahad, A. and Beutler, E. (1997) Gilbert Syndrome and glucose-6-phosphate dehydrogenase deficiency: A dose-dependent genetic interaction crucial to neonatal hyperbilirubinemia. Proc. Natl. Acad. Sci. USA. 94, 12128-12132, with permission. et al. 1999] . This variant is therefore also known as G71R, and is prevalent in Japanese, Korean and Chinese populations. Some other mutations reported in association with Gilbert's syndrome in Asian populations include Arg209Trp, Pro229Gln, Tyr486Asp and Arg367Gly [Maruo et al. 1998 , Hsieh et al. 2001 . A full list of coding area mutations encountered in over 400 Taiwanese neonates has recently been published and included heterozygous coding area UGT mutations, compound heterozygous coding area mutations in combination with 6/7 (TA) promoter heterozygosity, and homozygous coding area mutations .
While homozygosity for both the 7/7 UGT promoter polymorphism seen in Caucasians, and the G71R polymorphisms encountered in East Asia are associated with clinically apparent Gilbert's syndrome, the two polymorphisms appear to behave differently with regard to their ability to influence the development of neonatal hyperbilirubinemia. Maruo et al. [1999] , studying Japanese hyperbilirubinemic babies who had no obvious cause for their jaundice, determined the allele frequency of a mutated UGT 1A1 (G71R) to be more than double that of controls. Both hetero-and homozygosity for the G71R mutation were associated with hyperbilirubinemia. In contrast to Western babies with the variant 7/7 UGT 1A1 promoter, the Japanese neonates with the G71R mutation did not seem to require any additional jaundice provoking factors for their mutation to have its effect. It is possible that the high incidence of hyperbilirubinemia in Japanese newborns may be a function, in part, of the frequency of the G71R mutation in that population. Similarly, a recent study of Taiwanese neonates demonstrated that homozygosity for UGT mutations, primarily G71R, in the absence of additional risk factors including G-6-PD deficiency, resulted in a significantly higher relative risk of hyperbilirubinemia (STB >15.0 mg/dL) compared with subjects carrying the wild genotype (relative risk 5.2, 95% confidence interval 1.7-16.1, p=0.005).
Crigler-Najjar Syndromes Types 1 and 2
The Crigler-Najjar syndrome is, except in some inbred populations, a rare genetic condition characterized by very high serum levels of unconjugated bilirubin. If left untreated, the condition may lead to bilirubin encephalopathy and death. Several recent comprehensive reviews exist [Jansen 1996 , Jansen 1999 , Bosma 2003 , Sampietro and Iolascon 1999 , and its clinical aspects and molecular pathology will therefore be only briefly herein reviewed.
Crigler-Najjar syndromes result from a deficiency of the UGT enzyme. In type 1 there is complete deficiency of the enzyme. Serum bilirubin levels may be very high (>20.0 mg/dL) and, if untreated by phototherapy, may result in kernicterus with permanent neurologic damage, or death. Indeed, prior to the widespread use of effective phototherapy, this was the fate of affected children. This bleak outcome is not necessarily confined to the neonatal period, but may occur in later childhood or even in early adulthood. Serum bilirubin concentrations in type 1 CriglerNajjar syndrome are unresponsive to phenobarbital therapy.
Type 2 Crigler-Najjar syndrome is a more mild form of the disease. Serum bilirubin concentrations are usually lower, and may decrease by 30-80% in response to phenobarbital treatment. The response to phenobarbital may be absent in the first months of life, but become convincing during the second six months of life. Phenobarbital functions via a phenobarbital-responsive enhancer module which stimulates the UGT 1A1 gene to induce production of the bilirubin conjugating enzyme [Sugatani et al. 2001] . It should be noted that the differentiation between types 1 and 2 CriglerNajjar syndrome is not distinct but based to a large extent on the clinical picture, with no clear dividing line between the two.
The Crigler-Najjar syndromes may be diagnosed by studying the UGT gene for mutations typically associated with the condition (below), or by analyzing bile bilirubin pigment obtained via duodenal aspiration. In type 1 CriglerNajjar syndrome, the bile aspirate will be almost devoid of any conjugated bilirubin. In the type 2 form of the disease, monoglucuronides may be detected and, during phenobarbital therapy, some diglucuronide as well (Lee et al. 2001 , Sinaasappel and Jansen 1991 , Rubaltelli et al. 1994 . Measurement of UGT enzyme activity in liver biopsy tissue is also possible, but this is a complicated procedure and not routinely available. Crigler-Najjar syndrome is treated in the acute stages by actively reducing serum bilirubin levels, should they be in the range which may lead to kernicterus, by performing exchange transfusion. Phototherapy is a valuable therapeutic modality and frequently must be administered for many hours daily in order to control the hyperbilirubinemia. Calcium phosphate administration has been used as an adjuvant to phototherapy to bind with bilirubin in the bowel and prevent its reabsorption [van der Veere et al. 1997] . Type 2 patients should also be administered phenobarbital. Heme oxygenase inhibitors (metalloporphyrins) are currently being investigated for routine clinical use and may in the future be of value in the management of the Crigler-Najjar syndromes [Kappas 2004 ].
Meanwhile, liver transplant offers the only definitive treatment for the disease. This procedure should not be delayed indefinitely, as phototherapy may become less effective with the passage of time, and intercurrent illnesses may precipitate high levels of serum bilirubin, with the potential of kernicterus, even in children whose serum bilirubin concentrations had appeared to be under control, and who had appeared to be generally and neurologically intact. In a multicenter report of a world survey, 7 of 21 (33%) of transplanted children had already developed some form of brain damage at the time of their transplantation. Average age at transplantation was 9.1 ± 6.9 years (range, 1-23 years) [van der Veere et al. 1996] . Hepatocyte transplantation has also been used in a Crigler-Najjar patient (Fox et al. 1998 ], while gene therapy may also have promise for these patients in the future [RoyChowdhury 2001] .
Many different mutations in the UGT gene have been identified, which may cause both types 1 and 2 CriglerNajjar syndrome, as recently reviewed [Bosma 1999 , Jansen 2003 , Kadakol et al. 2000 . Most of these occur in the coding region of the gene. Mutations leading to type 1
Crigler-Najjar syndrome may be missense mutations, nonsense mutations, nucleotide deletions, mutations leading to a premature stop codon, mutations leading to frame shifts, and splice site mutations. Lack of enzyme activity may be due to these mutations leading to no enzyme-proteins, truncated enzymes or inactive full-length enzyme proteins. Missense mutations found in association with type 2 CriglerNajjar syndrome result in partial enzyme activity.
Homozygosity for the same mutation may be suggestive of parental consanguinity [Sampietro and Iolascon 1999] . Simple heterozygosity, i.e. the existence of two different alleles at a single designated locus for a UGT1A1 coding area mutation is not normally associated with neonatal hyperbilirubinemia. However, increased understanding of molecular genetics is making it apparent that heterozygosity may play a more important part in the pathogenesis of disease than was previously thought [Vladutiu 2001] . It is recognized that there is a spectrum of heterozygosity with various models of multiple gene heterozygosity, all of which combinations have the potential to contribute, sometimes subtly but on occasion more considerably, to disease phenotype. Some of these combinations include compound heterozygosity, implying the presence of two different mutations at a given locus, and double heterozygosity, involving the existence of a mutant allele at each of two different gene loci. Heterozygosity may involve interaction between mutant alleles in the coding and promoter areas of a gene. Many heterozygotic combinations have been described in association with the Crigler-Najjar syndrome. Kadakol et al. [2000] have compiled a listing of over 50 mutations of the UGT1A1 gene that may cause the Crigler-Najjar syndromes. Some recently reported examples of interesting genetic combinations in Crigler-Najjar syndrome include double homozygosity for G71R and Y486D [Yamamoto et al. 1998, Kraemer and Klinker 2002] , homozygosity for (TA) 8 promoter polymorphism in conjunction with a N400D UGT1A1 mutation [Labrune et al. 2002] , homozygosity for the (TA) 7 promoter defect juxtaposed on a coding area A-C substitution in one allele of common exon 5 at nucleotide 1391 [Chalasani et al. 1997] , other combinations of UGT1A1 promoter and coding area mutations [Kadakol et al. 2001] , and promoter mutation (TA) 8 combination with a coding area R336W mutation [Ciotti et al. 1998 ]. Recently, splice site mutations in the non-coding intronic region of the UGT1A1 gene have been reported. The mutations encountered in these patients were homozygosity for a GàC mutation at the splice donor site in the intron, between exon 1 and exon 2, heterozygosity for an AàG shift at the spliceacceptor site in intron 3, in combination with a premature translation-termination codon in the second allele of exon 1 [Gantla et al. 1998 ], and a GàA mutation at the splice acceptor site in intron 4 on one allele, with a TàA subsitution followed by a 13-nt deletion in exon 2 of the other allele [Sappal et al. 2002] .
Some of these defects demonstrate how seemingly innocuous genetic mutations, such as TA promoter polymorphism associated with Gilbert's syndrome may, when in combination with additional mutations in the same gene, interact to result in serious disease manifestations, in this case, severe hyperbilirubinemia. These mutations have practical implications as well: when offering genetic counseling regarding the likelihood of recurrence of severe neonatal hyperbilirubinemia or kernicterus in future offspring, heterozygotic mutations as well as homozygotic mutations should be taken into consideration. Molecular gene studies should also encompass the promoter region as well as the coding area.
Neonatal Hyperbilirubinemia Due to other UGT1A1 Coding Area Mutations
In an attempt to determine potential genetic factors responsible for the high incidence of neonatal hyperbilirubinemia in Asian neonates, studied the UGT1A1 gene in 123 Chinese neonates in Taiwan who developed serum bilirubin concentrations >15.0 mg/dL within the first week of life, and who did not have any obvious risk factor for jaundice, including prematurity, ABO blood group incompatibility, G-6-PD deficiency, sepsis, cephalhematoma, asphyxia or dehydration. The control group comprised 218 healthy, term neonates without risk factors for jaundice, and whose peak serum bilirubin values did not exceed 15.0 mg/dL in the first week of life. The promoter area, exons 1 to 4, coding region of exon 5, and the flanking intronic regions in the UGT1A1 gene were determined by PCR. The wild type gene was encountered significantly less frequently in the hyperbilirubinemic group than in the controls (37.4% vs. 49.5%, p=0.03). The mutation mainly responsible for this difference was that of a variation at nucleotide 211 (211 GàA). The incidence of serum bilirubin values >20.0 mg/dLwas significantly higher in those homozygous for the mutation (6/14, 42.9%) than those carrying the wild type (8.7%, p=0.01) or other genotypes (12.7%, p=0.02). These authors concluded that the 211 G>A mutation is a significant risk factor for neonatal hyperbilirubinemia, in the absence of any other obvious icterogenic factor. went on to study the effect of UGT1A1 mutations in the precipitation of neonatal hyperbilirubinemia in G-6-PD deficient neonates. The full sequence of the UGT1A1 gene was analyzed for 212 male G-6-PD deficient and 232 control male G-6-PD normal neonates. The predominant G-6-PD mutations encountered included 1376 GàT and 1388 GàA. No significant differences were noted between the overall incidence of the wild type UGT1A1 gene, or any of the coding area or promoter region mutations. However, the incidence of hyperbilirubinemia was significantly greater in those homozygous for the 211 GàA variation compared with those with the wild type gene, both for the G-6-PD deficient neonates, all 14 of whom developed hyperbilirubinemia (relative risk 6.4, 95% confidence interval 3.3-12.1) and for the G-6-PD normal controls (relative risk 5.2, 95% confidence interval 1.7-16.1). Increased incidence of hyperbilirubinemia among G-6-PD deficient neonates was limited to those homozygous for the 211 GàA mutation. These findings compare favorably to, and confirm the findings of those of Kaplan et al. [1997] (above) who described an interaction between the G-6-PD Mediterranean mutation and TA promoter polymorphism of the UGT1A1 gene. One contrasting feature between Kaplan et al. 's study and that of Huang et al. is that in the former, 6/7 heterozygosity for the promoter polymorphism also conferred a higher incidence of neonatal hyperbilirubinemia within the G-6-PD deficient group, although not to the same extent as 7/7 homozygotes. Also, (TA) 7 homozygosity, in the absence of G-6-PD deficiency, did not lead to a significantly higher number of hyperbilirubinemic neonates compared with the wild type, whereas in the Chinese neonates, homozygosity for the 211 GàA mutation, in the G-6-PD normal control group, did. While overall, it is now apparent that G-6-PD deficiency does tend to interact with UGT1A1 gene mutations to precipitate neonatal hyperbilirubinemia, differences in these interactions between various population groups may arise due to either differences in the type of G-6-PD mutation, or because of the variation in the type of UGT1A1 mutations.
Interaction Between UGT1A1 Coding Area Mutations and G-6-PD Deficiency
E. THERAPEUTIC IMPLICATIONS
For several decades, the mainstay of therapy for neonatal hyperbilirubinemia has been phototherapy, with exchange transfusion held in reserve for those cases that do not respond to intense phototherapy. More recently, intravenous immune globulin administration has been utilized in order to diminish hemolysis in situations of isoimmunization due to blood group incompatibilities [Rubo et al. 1992 . Pharmacologic preparations such as phenobarbital have been used to induce UGT enzyme activity [Valaes et al. 1980] . Metalloporphyrins have shown promise in preventing bilirubin production by inhibiting heme oxygenase activity [Kappas 2004 ] and may have a special role in G-6-PD deficiency [Valaes et al. 1998 , Kappas et al. 2001 . Several recent overviews of pharmacologic approaches to the treatment of neonatal hyperbilirubinemia exist (Dennery 2002 , Hansen 2003 ] With the exception of gene therapies being tried for Crigler-Najjar syndrome type 1, none of these therapeutic modalities is genetically oriented, and further description is therefore beyond the scope of this article.
Gene Therapy for Inherited Hyperbilirubinemia
Most conditions leading to neonatal hyperbilirubinemia are self-limited and, provided that neurologic damage is prevented in the neonatal period, no further treatment or follow-up is necessary. The exception to this is CriglerNajjar syndrome type 1, the manifestations of which may continue into adulthood, with the development of kernicterus far after the neonatal period. As a result, permanent therapies are necessary. Currently, orthoptic liver transplant is the only practical option. However, as the liver architecture remains intact in this condition, cell and gene therapies, with the aim of partially correcting UGT1A1 enzyme activity, are being investigated. The animal model of the disease is the Gunn rat, deficient in UGT. It is estimated that 10% replacement of gene activity should be sufficient to prevent kernicterus in these patients. Some techniques currently under investigation include ex vivo delivery of UGT1A1 to the liver, by which liver cells with the mutant gene are isolated, a therapeutic gene integrated into the cell genome, and the phenotypically corrected cell transplanted back into the donor. Immunosuppression is unnecessary, as the hepatocytes are autologous. UGT1A1 can be delivered to the Gunn rat liver in vivo, providing glucuronidating activity, using either nonviral methods such as receptor-mediated endocytosis or F virosome-mediated gene transfer, or by using viral vectors, which have included retroviral and adenoviral vectors. Site directed gene repair, exploiting natural cellular gene repair mechanisms, has been used to treat single nucleotide mutations or deletions. Both ex vivo and in vivo techniques have been used with some success in restoring UGT1A1 activity to Gunn rats, and it is hoped that these successes will make gene therapy of Crigler-Najjar syndrome type 1 a reality in future years .
F. CONCLUSIONS
Neonatal hyperbilirubinemia is an important condition because of the rare, but tragic, potential of permanent neurologic damage (kernicterus). Hyperbilirubinemia may be due to lack of equilibrium between the processes either increasing bilirubin production, or diminishing its elimination. Recent understanding of these entities has made it evident that there is a genetic basis to many of the conditions which may contribute to the development of hyperbilirubinemia. Frequently, various genetically based icterogenic mechanisms may interact to further increase lack of equilibrium between the bilirubin producing and eliminating processes. Benign conditions such as Gilbert syndrome become potentially serious when in the presence of factors increasing hemolysis, such as G-6-PD deficiency. Minimally increased hemolysis may result in severe hyperbilirubinemia when combined with diminished bilirubin conjugation. Usually clinically insignificant heterozygotic mutations may become significant when in combination with an additional heterozygotic mutation.
On a practical level, awareness of the genetics of bilirubin production and conjugation, and modern day ability to positively identify mutations of the genes encoding these processes may become useful in the identification of neonates at risk for developing severe hyperbilirubinemia. The neonate whose genome may put him or her at risk for hyperbilirubinemia may be identified by taking a history from parents enquiring into ethnic background, risk factors, and previous infants with hyperbilirubinemia. A history of jaundice in the parents may suggest Gilbert's syndrome with the presence of TA promoter polymorphism in their offspring. Physical examination and a few simple laboratory tests including blood group determination, direct Coombs' testing, G-6-PD screening where appropriate and end tidal carbon monoxide testing where available ] may further single out neonates whose genetic endowment places them at risk for significant hyperbilirubinemia. In selected cases, such as severe, unexplained familial hyperbilirubinemia, it may be appropriate to refer a family for genetic counseling and to obtain genotype analysis of the UGT 1A1 gene. Prudent evaluation may facilitate prediction of severe jaundice and enable prevention of bilirubin encephalopathy in future siblings. 
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